Proximal humerus fractures (PHF) are common injuries. At the age of 60 and above, no clinically important difference between surgical and non-surgical treatment after one year has been reported based on a recent Cochrane review of 10 trials.
The treatment of choice for displaced PHF in adults 50-65 years is anatomical reconstruction, and osteosynthesis if possible, which is why many patients in this age group with a displaced PHF undergo surgical treatment.
Orthopaedic surgeons may encounter challenges in guiding patients and formulating treatment strategies within specific age groups due to the absence of inclusion of this younger patient demographic in existing evidence. Knowledge is primarily derived from studies on the population aged 60 years and above. There exists an intermediate age group of patients for whom it remains uncertain whether the benefits and harms of non-surgical and surgical interventions are comparable
This trial is a two-center, parallel-group, randomized, superiority trial comparing osteosynthesis with non-surgical treatment following a displaced proximal humerus fractures in patients aged 50-65 years. The participants will be included and allocated equally to surgical treatment with osteosynthesis (comparator) with non-surgical treatment (intervention).
The surgical group will visit the outpatient clinic after 2, 12, and 24 weeks, while the non-surgical group will visit after 6, (12) and 24 weeks. X-rays will be obtained before every visit.
Both groups will be referred to rehabilitation in the municipalities.
Without a patient-derived MCID for PHF, a relevant difference of 9,6 was assumed to represent clinically meaningful difference. This is equivalent to approximately a 20 % difference between the surgical group and the non-surgical group on a 0-48 OSS scale. With a power of 80% and a 5% level of significance, a sample size of 25 participants per group is required. Assuming a 15 % loss to follow-up, the recruitment target is 30 patients in each group, meaning 60 participants overall.
In case of treatment failure in either group, defined as persistent pain or a failed osteosynthesis, a salvage procedure with secondary osteosynthesis or a reverse shoulder arthroplasty (RSA), will be offered.
Additionally, there are plans for a systematic collection of reasons for non-inclusion of eligible patients who were not recruited into the trial (decliner cohort), and their baseline characteristics, treatment preferences. The decliner cohort will receive the same treatment, follow-up, and outcome measurements as the included patients.
Statistical analysis:
Baseline characteristics will be presented using descriptive statistics. Investigators will compare the following patient characteristics between the groups at baseline: age (categorized into 5-year age groups), sex, height, weight, ASA score, fracture classification (Neer), dominant arm (yes/no), smoking, alcohol consumption, educational level, working status, work type, osteoporosis (three-level ordinal variable based on T-scores (osteoporosis, osteopenia, and normal bone density)) and clinical frailty scale. SD will be reported, and n (%) for categorical values.
Osteoporosis will be collected and reported descriptively as a three-level ordinal variable based on T-scores (osteoporosis, osteopenia, and normal bone density).
The OSS results for surgical and non-surgical treatment groups at 6, 12, and 24 months will be tabulated and graphically represented with mean, SD, median, and IQR according to the distribution.
The primary outcome, OSS at 12 months, will be analysed using two-sample t-test comparing the two treatment groups. Normality assumptions will be assessed, and if violated, alternative methods such as transformation or non-parametric Mann-Whitney U test will be considered. As suggested in the extension of the CONSORT 2010 statement, the primary outcome will be analysed for the intention-to-treat (ITT) population.
In addition, linear mixed models will be used to analyse OSS and EQ-5D over time (6, 12 and 24 months) accounting for the repeated measures structure and to explore outcome trajectories. Model-based contrasts from the LMM will be used to estimate adjusted between-group differences at specific time points. Missing data will be handled within the mixed model framework, assuming data are missing at random. Details are provided in Supplementary Information, file 4.
Investigators will record and report adverse events in each group. At the 6-month follow-up, patients will be asked, and investigators will record and report the length of rehabilitation in municipalities (in weeks) and whether the patient has followed the rehabilitation plan.
Salvage procedure Salvage procedures and adverse events will be reported descriptively. Reoperation in the form of hardware removal will be classified as a complication, not a salvage procedure. There will be two analyses for ITT: one including salvage procedures and one excluding them. The timing of salvage procedures will be analyzed using a Cox proportional hazards model to compare time to salvage between treatment groups.
Non-randomized cohort (decliner cohort) Patients who declined randomization but consented to follow-up will form the non-randomized cohort. Baseline characteristics will be summarized descriptively and compared between the randomized and non-randomized cohorts, as well as among the non-randomized patients by treatment choice. The primary outcome (OSS at 12 months) will be analyzed by treatment modality. Secondary outcome measures (OSS and EQ-5D) will be presented descriptively and graphically at 6, 12, and 24 months. Analyses will include multivariable linear regression adjusted for baseline covariates; propensity score methods may be applied. The incidence and timing of salvage procedures will be described and analyzed using Cox proportional hazards models.
Blinded data interpretation Although patients and investigators are not blinded to treatment allocation, the primary investigator will conduct blinded statistical analysis through data anonymization and will be supervised by a biostatistician. The OSS and EQ-5D-3L will be completed just before the 6-month visit, collected automatically through REDCap, and will not be reviewed by the investigator prior to analysis- After the blinded statistical analysis has been completed, two abstracts will be written based on the pre-blinding analysis results before the blinding is revealed.
Data will be analysed using the statistical "R" .
Interim analyses An interim analysis will be conducted when 50% (n = 30) of the randomized patients have completed their 6-month follow-up, focusing on OSS, failure to treatment, and serious complications. A third party will blind the data to treatment location before analysis. Regardless of whether the interim analyses suggest that the study is unlikely to achieve its primary objectives, the study will proceed as initially planned.
A DMC has been organized to monitor and evaluate the data from the interim analysis. The DMC consists of four independent members, including four orthopedic researchers and an orthopedic nurse.
The DMC will monitor unexpected, unwanted events; continued inclusion will be considered if the failure rate is above 30 %. Intervention-related hospitalization or mortality will be reported to the ethics committee.
